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Stratified analyses of genome wide
association study data reveal haplotypes
for a candidate gene on chromosome 2
(KIAA1211L) is associated with opioid use in
patients of Arabian descent
Hiba Alblooshi1,2,3, Habiba Al Safar4,5, Ahmed El Kashef6, Hamad Al Ghaferi6, Mansour Shawky6, Gary K. Hulse1,7 and
Guan K. Tay1,4,5,7*

Abstract
Background: Genome Wide Association Studies (GWAS) have been conducted to identify genes and pathways
involved in development of opioid use disorder. This study extends the first GWAS of substance use disorder (SUD)
patients from the United Arab Emirates (UAE) by stratifying the study group based on opioid use, which is the most
common substance of use in this cohort.
Methods: The GWAS cohort consisted of 512 (262 case, 250 controls) male participants from the UAE. The samples
were genotyped using the Illumina Omni5 Exome system. Data was stratified according to opioid use using PLINK.
Haplotype analysis was conducted using Haploview 4.2.
Results: Two main associations were identified in this study. Firstly, two SNPs on chromosome 7 were associated
with opioid use disorder, rs118129027 (p-value = 1.23 × 10 − 8) and rs74477937 (p-value = 1.48 × 10 − 8). This has
been reported in Alblooshi et al. (Am J Med Genet B Neuropsychiatr Genet 180(1):68–79, 2019). Secondly,
haplotypes on chromosome 2 which mapped to the KIAA1211L locus were identified in association with opioid use.
Five SNPs in high linkage disequilibrium (LD) (rs2280142, rs6542837, rs12712037, rs10175560, rs11900524) were
arranged into haplotypes. Two haplotypes GAGCG and AGTTA were associated with opioid use disorders (p-value
3.26 × 10− 8 and 7.16 × 10− 7, respectively).
Conclusion: This is the first GWAS to identify candidate genes associated with opioid use disorder in participants
from the UAE. The lack of other genetic data of Arabian descent opioid use patients has hindered replication of the
findings. Nevertheless, the outcomes implicate new pathways in opioid use disorder that requires further research
to assess the role of the identified genes in the development of opioid use disorder.
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Background
Epidemiological data from the 2010 Global Burden of
Diseases Health Measurement Survey estimated that
some 15.5 Million people across the globe were afflicted
with opioid use disorder [1]. As a measure of the chronic
nature of the problem, the use of opioids significantly
rose in the United States of America (USA) to epidemic
proportions with a dramatic increase of 78% in 2013 [2].
Opioids of choice included heroin, as well as the substances morphine, fentanyl, oxycodone and tramadol
which are widely used as prescribed analgesics for surgery [3]. The rise in the use of prescribed opioids for
non-medical purposes has been reviewed in many countries [4]. The USA is considered the epicentre of the
world’s prescription drugs problem, where a 10 to 14fold increase in prescription medication has been estimated [5, 6]. The consumption of prescription medication for non-medical use resulting in harmful effects in
2010, was highest in the USA at 47,809 (consumption
level per capita), followed by Canada (26,380), the
United Kingdom (UK) (10,297) and Australia (12,654)
[7]. In addition, there was a massive increase of 430% in
the number of treatment admission for prescription
medication misuse between 1999 to 2009 in the USA
[6]. Even though, there been as a dramatic increase in
the prescription medication misuse in Europe, it is not
as prevalent in the UK in comparison to the USA [8, 9].
This is due to the strict regulation and legislations that
control the use of prescription medication in the UK
through the implementation of an electronic prescription system [4]. However, around 30% of patients with
prescribed medication in the UK tend to sell or swap
their allocation with other medications that contribute
to the problem [10]. In North Africa and Middle East region, an estimated 1.37 million patients reported the use
of opioids in 2010 [1]. In the first retrospective study of
substance use disorder (SUD) in the United Arab Emirates (UAE) from 2002 to 2011, opioids (heroin = 16.3%)
were the second most common substance of use [11].
This pattern of prescription opioid use in the young
(below the age of 30 years old) users from the UAE was
recently described in Alblooshi et al (2016) [12]. The use
of prescription opioids such as Tramadol rose by an estimated 67.2% in users below 30 years of age [12, 13]. This
cohort was used in this study.
The vulnerability to substance use and treatment responses is partly affected by genetic factors [14–16] .
The Identification of genes that contribute to the development of the disease can improve treatment outcomes
of SUD. Opioid receptors (OPRM1, OPRD1 and OPRK1)
have been extensively studied in addiction due to their
involvement in the reward pathways. The μ-opioid receptor (OPRM1) has been the main focus in opioid use
disorder. Various Genome Wide Association Studies
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(GWAS) [17–19] have looked into the genetic factors
contributing to opioid use disorder. However, inconsistent genetic associations have been reported, suggesting
that there are other systems involved in the pathogenesis
of the opioid use disorder [20]. In the first GWAS study
by Gelenter et al (2014) [17] the KCNG2 (rs62103177)
gene on chromosome 18 was implicated. The association
was mapped to a Calcium and Potassium pathway, a
novel risk pathway that provided a new direction for
therapeutic and preventative strategies [17]. Nelson et al
(2015) [21] subsequently reported an association of the
cornichon family AMPA receptor auxiliary protein 3
gene (CNIH3) with heroin use disorder. This finding implicated the involvement of the glutamate system in the
pathophysiology of opioid use disorder. To date, a number of genes, including LOC647946, FAM53B, CRYGS
which encode proteins involved in different biochemical
pathways have been reported. Presently, no definitive
mechanism has been uncovered to explain the underlining pathophysiology of the opioid use disorder.
In many polygenic diseases, ethnic specific genetic variations have been described. In opioid use disorder, various GWA studies have been performed and reported in
European American, African American [17, 22] and
Australian population [21]. However, none have been
performed on an Arab population. In this study, the first
GWAS of SUD in a population of Arabian descent was
conducted. The subjects were opioid users as this substance class was the most common substance of use at
80.4% [12] of the cohort studied. Three novel variants
on chromosome 7 were identified and discussed in
Alblooshi et al [23]. In this report, associations with haplotypes on chromosome 2 around the KIAA1211L locus
are presented.

Methods
Participants

The GWAS discovery samples consisted of 262 male
participants from the UAE. Cases included 250 male patients from the UAE National Rehabilitation Centre
(NRC). All cases were diagnosed with SUD based on
Diagnostic and Statistical Manual-5 (DSM-5) criteria.
However, cases were not assessed for other psychiatric
disorders at the time of recruitment. Controls with no
prior history of SUD were retrieved from the Emirates
Family Registry (EFR) [24] as a control group. However,
other diseases were included in the control group selection criteria such as diabetes, cardiovascular diseases,
dyslipidaemia, etcetera. The details of the cohort have
been previously summarised in Alblooshi, et al (2016)
[12] including the demographic characteristic and the
type of substances used. The cohort was stratified based
according to the common substance of use, which was
opioids.
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The study was conducted in accordance with standards set by the World Medical of Helsinki [25]. The
ethics committee of the National Rehabilitation Centre
(NRC) in Abu Dhabi, UAE reviewed and approved the
study. Reciprocal approvals were received from the ethics committee of the University of Western Australia
(RA/4/1/6715). Only participants who signed written informed consent were studied.
Genotyping and quality control

Saliva samples were collected using the Oragene saliva
kit (DNA Genoteck, Ottawa, Ontario, Canada). Genomic
DNA was extracted using laboratory protocol for manual
extraction as recommended by Genoteck. Each sample
was processed for quantification using standard gel electrophoresis and Tecan NanoQuant Plate™ (Infinite 200
Pro) (Tecan Group, Männedorf, Switzerland). After
extracting genomic DNA, the samples were genotyped
using the Illumina Omni5 Exome (Illumina, San Diego,
California), which contained 4.6 million Single Nucleotide Polymorphism (SNPs). Standard protocols as recommended by Illumina were used for hybridizing
samples on the chip and scanning on the Illumina HiScan platform.
Quality Control (QC) step was applied on markers and
individuals using PLINK [26]. The markers were filtered
based on a genotype call rate < 99.6%; Minor Allele Frequency (MAF) < 0.05; significant deviation from Hardy
Weinberg Equilibrium (p-value < 10− 6) and large difference (p-value < 0.00001) in missing data rate between
cases and controls. The individuals were removed from
the analysis where there was substantial missing data (>
90%); when whole genome heterozygosity was greater
than three standard deviation from the mean; estimated
proportion of “identity by descent” (IBD) sharing with
another sample > 0.1, or gender discordant (based on X
chromosomal heterozygosity) > 0.2. Multi-dimensional
scaling (MDS) was carried out to identify population
outliers. After filtering for individuals, 199 cases with
opioid use disorder and 262 controls were retained final
analysis.
Statistical analysis

For the data stratified according to opioid use disorder, a
total of 1,879,623 SNPs and 452 (Case:199 and Control:
253) passed QC. These were included in the study analysis. The GWAS association test was preformed using
Factored Spectrally Transformed Linear Mixed Model
“FaST-LMM” [27]. Quantile-Quantile (QQ) and Manhattan plot were illustrated using R statistical package (R
core team, Vienna, Austria). The GWAS significant level
was set at 5.00 × 10− 8 [28]. The Regional Manhattan plot
showing the SNP positions of interest were plotted using
zoom locus webserver [29]. PLINK [26] was used for
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stratification of common substance of use. Haploview
4.2 [30] was used for haplotype and linkage disequilibrium (LD) analyses.

Results
In this report, analysis from a GWA study of SUD patients using opioids is presented. Fig. 1 shows the stratified GWAS Manhattan plot for opioid use disorder. In
the analysis, two SNPs reached significant association
with p-values of 1.23 × 10 − 8 and 1.48 × 10 − 8 for
rs118129027 and rs74477937 respectively. These SNPs
were localized to chromosome 7. Another SNP
rs78707086 on chromosome 7 failed to reach the set
GWAS significance level (p-value = 5.00 × 10− 8) but was
suggestive of an association. Nevertheless, this third SNP
was in LD with rs118129027 and rs74477937. The relevance of these three SNPs in SUD has been reported
elsewhere [23].
A second association is described in this paper. Between the GWAS level of significance (5.00 × 10− 8) and
the suggestive level (1.00 × 10− 5), seven SNPs on
chromosome 2 formed a cluster with five of these SNPs
in LD (Fig. 1). This suggested the possibility of candidate
locus on chromosome 2 associated with opioid use
disorder.
The cluster of SNPs circled in Fig. 1 highlight the nucleotide positions that have risen above the suggestive
GWAS confidence level. A regional manhattan plot (Fig. 2)
was generated around the location of these SNPs, partly to
assess Linkage Disequilibrium (LD) between the SNPs.
The recombination rates are shown in centimorgans (cM)
per megabase (Mb). Each SNP is represented as a circle
with the y-axis shown as -log10 p-value. The SNP with the
highest p-value (rs10175560 with a p-value = 2.24 × 10− 7)
was selected as the index SNP (purple diamond in Fig. 2).
Linkage disequilibrium (LD) values with other SNPs in the
vicinity of this index were estimated in r2 values and shown
in different colours. The LD correlation was estimated
using the data from the 1000 Genome project [29]. The
highest LD is shown in red were for SNPs with r2 > 0.08.
SNPs with no LD data were represented by grey circles.
Genes within the vicinity of the SNP of interest are provided. In this figure, the suggestive SNPs mapped to a region coinciding with a locus known as KIAA1211L. In
addition, Fig. 2 illustrated strong LD that suggested further
haplotype analysis for an association and improved evidence for candidate genes.
The SNPs on chromosome 2 that were above the suggestive line of 1.00 X 10 − 5 determined by this GWA
study are shown in Fig. 3. The data was not adjusted for
other psychiatric disorder; hence the association level
might be altered. Five out of seven SNPs on chromosome 2 above this suggestive line were in LD
(rs2280142,
rs6542837,
rs12712037,
rs10175560,
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Fig. 1 Manhattan plot shows p-value for stratified opioid users versus normal controls using FaST-LMM analysis. The X-axis represents the SNP
markers in each chromosome and Y-axis represent the negative logarithm of P-values. The highest p-values were observed for rs118129027(pvalue = 1.236 X 10 − 8) and rs74477937 (p-value = 1.485 X 10 − 8) on chromosome 7. The circle indicates a candidate haplotype that associated
with opioid use disorder

Fig. 2 Regional Manhattan plot of the chromosome 2q11.2 region showing the FaSTLMM analysis of the opioid use disorder patients compared
to controls. The LD heat map is based on the hg19/1000genomes NOV/2014 reference set. The SNPs are colour coded according to r2 measured
based on the pairwise LD with the index SNP rs10175560 (p-value = 2.24 × 10 − 7) shown in purple. Two other SNPs mapped to the KIAA1211L
gene clustered in high LD indicating a possible candidate locus for opioid use disorder
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Fig. 3 The state of the LD between the SNPs located above the GWAS suggestive line 1 X 10 −5on chromosome 2, based on opioid use disorder
patients compared to controls from the UAE population. Block 1 includes 5 SNPs mapped to the KIAA1211L gene that are significantly associated
with opioid use. The numbers in the square represent the percentage of the r2 value calculated from the genotype data of the SNPs. The
haplotype variations, frequencies and P-values illustrated with the GAGCG (p-value = 3.26 X 10− 8) haplotype the most significant

Fig. 4 The distribution of the haplotypes in block 1 that include 5 SNPs between opioid users and controls. Haplotype 1 (GAGCG) the most
statistically significant with higher frequency (0.713) in control group. Haplotype 2 (AGTTA) higher in cases (0.369) than control (0.219)
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rs11900524). These 7 SNPs were organized into haplotypes, with block 1 including the five SNPs: rs2280142,
rs6542837, rs12712037, rs10175560, and rs11900524.
Two haplotypes GAGCG and AGTTA were associated
with opioid use disorders at p-values of 3.26 × 10− 8 and
7.16 × 10− 7, respectively.
Fig. 4 provides a summary of the 5-point haplotype
frequencies for block 1 in opioid users and controls. The
frequency of haplotype 1 (GAGCG) at 0.713 was higher
in the control group relative to the cases. In contrast,
the frequency of haplotype 2 (AGTTA) was higher in
cases (0.369) than in the control group (0.219).
The analysis was extended to include the chromosome
2 SNPs above the p-value 1 × 10 − 4. Linkage Disequilibrium data of 31 SNPs is shown in Additional file 1: Figure. S1. Six haplotype blocks were constructed using
these 31 SNPs. Block 1 and 2 mapped to the chromosomal region that coincided with KIAA1211L. Additional
file 2: Table S1 also provides a summary of the haplotype distribution, the frequencies of each haplotype, and
p-value of the cases and control groups.
A number of locations on chromosome 2 was shown
to be associated with substance use and other psychiatry
disorders. Fig. 5 summaries these association including
the KIAA1211L loci identified in this study.

Discussion
This study is an extension of a GWA study, the first of
its kind, involving SUD patients in the UAE population.
In the initial GWAS, three SNPs: rs118129027,
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rs74477937 and rs78707086 were below the GWAS significance level but highly suggestive of an association.
These mapped to a region on chromosome 7, which coincides with the YAE1D1 locus. Separately, the function
of this gene was discussed as a possible candidate locus
for substance use disorder [23]. For this study, the initial
GWAS was stratified based on the most common substance of use, which were opioids. These are the most
common substance of use in the cohort and included
both illicit (e.g. heroin) and prescription medication (e.g.
Tramadol). Following data stratification two SNPs:
rs118129027 and rs74477937 on chromosome 7 were
found to be significantly associated with opioid use disorder. A third SNP rs78707086 did not achieve GWAS
significance levels however, it was considered as a potential SNP as it was in strong LD with the top two SNPs
(rs118129027 and rs74477937).
Just below the level of significance for GWA studies
set at 5.00 × 10− 8, seven SNPs on chromosome 2 suggested a potential locus that was associated with opioid
use disorder (highlighted in Fig. 1) and considered
worthy of further analysis. Five of the SNPs mapped to
the KIAA1211L gene as illustrated in the regional Manhattan plot of chromosome 2q11.2 (Fig. 2). The SNP
rs10175560 was used as the index SNP and was shown
to be in high LD with other SNPs mapped to
KIAA1211L. This could be a possible candidate locus
however, the function of KIAA1211L is not yet known.
Nevertheless, an association between KIAA1211L was reported in a study involving bipolar disorder [31]. In a

Fig. 5 Published associations for chromosome 2q regions from 2q11 to 2q34 and SUD as well as other psychiatric disorders
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study by Castellanie and colleagues (2014) [32] studied
copy number variants (CNVs) in six monozygotic twin
pairs for differences in schizophrenia. The monozygotic
twins discordant (MZD) approach has been successful in
identifying rare variants in schizophrenia. The CNV result in, loss (deletion) or gain (duplication/amplification)
of a particular segment of the genome. Castellanie et al
(2014) [32] reported CNV loss in KIAA1211L in the
monozygotic twin pair to be unique in the affected pair
with paranoid schizophrenia and not reported in the
normal twin pair. This was the first report of this CNV
in the database of genomic variants (DGV). Consequently, this CNV loss suggests that this region carries a
potential candidate for schizophrenia. In addition, Hicks
et al (2016) [33] investigated molecular markers in children with acute lymphoblastic leukaemia (ALL) Central
Nervous System (CNS). The current treatment strategy
for ALL is a combined systemic chemotherapy and
CNS-directed treatment (cranial radiation, intrathecal
methotrexate, or combination). The CNS classification is
important in ALL patients in order to determine the efficiency of CNS-directed the therapy. The current classification is based on the presence of blast cells in the
cerebrospinal fluid (CSF). It is classified to CNS1 (no detectable blast cells), CNS2 (presence of < 5 leukocytes
per μl with detectable blast) and CNS3 (presence of > 5
over CNS leukaemia with identifiable blast) [34]. In
order to avoid over-treatment or under-treatment in
children with ALL, there is a demand for precision assessment of CNS disorders from those without by identifying molecular markers that distinguish each class of
CNS. Hicks et al (2016) [33] investigated the differences
between gene expression of each level of the CNS in patients. They reported 40 highly significant genes
expressed differently between patients with CNS2 and
CNS3. The KIAA1211L was identified as one of the significant highly expressed genes (4.25 X 10− 4) in patients
with CNS3 [33]. This can help in determining the intensity of the CNS-directed therapy. Therefore, KIAA1211L
can be flagged as distinguishing molecular markers for
CNS3 typed patients with ALL. The overall finding highlights the involvement of KIAA1211L in psychiatric disorders or within the central nervous system and adds
weight in support of our results that suggest an association between KIAA1211L and opioid use disorder.
In this study, we also investigated SNPs that were in
LD with the index SNP rs10175560. The haplotype compositions and their respective frequencies are illustrated
in Fig. 3. In block 1, two haplotypes (GAGCG and
AGTTA) were significantly associated with opioid use
disorder. For haplotype 1 GAGCG the frequency in controls (0.713) was higher than in the cases (0.535), suggesting a possible protective role to opioid use (Fig. 4).
On the other hand, haplotype 2 AGTTA was higher in
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cases (0.369) when compared to the control group
(0.219) that suggest possible involvement of this haplotype in the development of opioid use disorder. The
remaining three haplotypes that were characterized
(GATTA, GAGCA and AGGTA) were not statistically
significant with opioid use (Fig. 4).
By expanding the haplotype analysis to include SNPs
on chromosome 2 from the p-values from 1 × 10− 8 to
1 × 10− 4, six blocks were generated and illustrated in
Additional file 1: Figure. S1. The haplotype variations in
each block with the classification between cases and
controls are summarised in Additional file 2: Table S1.
Block 1 and block 2 mapped to the KIAA1211L gene
and suggests a potential role in opioid use disorder. In
Block 1, two haplotypes, namely CTAAGT (p-value =
5.51 × 10− 8) and TCTGAC (p-value = 2.19 × 10− 7) were
significantly associated with opioid use. The 2 SNP block
3 mapped to the ACOXL (acyl-CoA oxidese like) gene
with the GA combination (p-value = 7.69 X10− 7) shown
to be the most significant haplotype. Blocks 4 and 5
mapped to the VWC2L gene (von Willebrand factor C
domain containing protein 2 like) and block 6 mapped
to OR6B3 (olfactory receptor family 6 subfamily B member 3). There were no direct associations found in the
literature between these genes and SUD or specifically
opioids. Nevertheless, further investigation would be required to understand the associations reported here and
possible mechanisms that may link these genes to opioid
use.
Various studies [3, 18, 35–37] have discussed the importance of the q-arm region on chromosome 2 in SUD
and other psychiatric disorders (Fig. 5). The NCK2 gene
is located on the long arm of chromosome 2 (2q12.2) is
located proximally to the region of the KIAA1211L locus
identified in this study. Liu et al (2012) [18] reported a
significant association between a SNP (rs2377339) on
NCK2 (p-value = 3.12 × 10− 8) with opioid use disorder in
a population of African descent. The NCK family is classified as a group of adaptor proteins that interact with
other proteins. Specifically, it is involved in the regulation of receptor protein tyrosine kinase signalling and
the regulation of actin cytoskeleton and cell movement
[32]. These findings suggest evidence for the involvement of the NCK2 in the pathway of opioid use disorder,
that highlight the potential role of the KIAA1211L locus
in the disorder.
Another genetic region in close proximity to
KIAA1211L contains the Diazepam Binding Inhibitor
(DBI). The DBI loci on chromosome 2q.14.2 encodes for
a protein that has been suggested to be involved in the
regulation of number of functions in the CNS, including
responses to stress, depression, anxiety and neuropsychiatric disorder [35]. Based on the chromosomal position
and the proximity of the DBI to the KIAA1211L, the
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possible involvement of the KIAA1211L in the CNS
should be explored.
Another region of interest on chromosome 2 was
mapped to a region bound by 2p14 and 2q14.3. This region has been studied in the context of various behavioural conditions, alcohol dependence, suicide attempts
and conduct disorder have been implicated [36]. Dick
et al (2010) [36] provided evidence for the involvement
of 23 genes (NTSR2, TRIB2, PPM1G, MEM01, HAAO,
MTIF2, CCDC139, EHBP1, BUB1, TTL, CKAP2L,
MGAT5, ARHGAP15, KIAA1189, COBLLI, FAM130A2,
LPR2, CHN1, PRKRA, PPP1R1C, LOC402117, IL8RA,
FARP2) on chromosome 2 in alcohol dependence. These
genes potentially contribute to alcohol dependence, conduct disorder and/or suicide attempts. Other regions
across chromosome 2 have been significantly associated
with a range of psychiatric disorders. Riley et al (2015)
[37] reported genomic imbalance for the region between
2q11.2 and 2q13 in patients with selected clinical
symptoms including developmental delay, intellectual
disability and congenital anomalies. A deletion in the
region from 2q12.2 to 2q13 has been reported in patients with developmental delay and dysmorphic features [38]. Furthermore, a deletion in the 2q21 region
was reported in patients with developmental delay/intellectual disabilities, attention deficit hyperactivity
disorder, epilepsy and other neurobehavioral abnormalities [39]. The overlap of the regions between
studies implicate gene(s) with the CNS that could potential contribute to the disorder.

Conclusion
Overall, findings in this study propose KIAA1211L as a
putative candidate locus associated with opioid use disorder. Even though, the function is not fully understood,
the region contains genes that are involved in the expression and function of the CNS proteins. In addition,
the evidence presented here supports the role of this region in psychiatric disorders, including SUD. Future
studies should consider replication of the KIAA1211L
locus in a larger cohort, including groups of individuals
of Arabian descent. In addition, more research is required to investigate the role of KIAA1211L in opioid
use disorder and other substances. Further assessment
of haplotype variations, specifically with reference to
opioid use is required in order to understand their
roles in opioid use disorder. Future research should
consider in depth sequencing of the KIAA1211L gene
and the surrounding region, comparing variants in
opioid use patients and controls to reveal any further
genetic associations in order to contribute to the understanding of underlining mechanisms that result in
the disorder.
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12888-019-2425-8.
Additional file 1 Figure. S1. The state of the LD of the SNPs located
between the GWAS line and suggestive line (1 X 10 − 8 -1 X 10 − 4) on
chromosome 2, based on opioid use disorder patients compared to
controls from the UAE population. Block 1, 2 mapped to the KIAA1211L
gene and is significantly associated with opioid use disorder in this
cohort.
Additional file 2 Table S1. The distribution of haplotype association
between the GWAS line and suggestive line (1 X 10 − 8 -1 X 10 − 4) on
chromosome 2 based on opioid users’ patients compared to controls
from the UAE population.
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